Tech Company Financing Transactions

Merganser Biotech Funding Round

On 2/19/2015, Merganser Biotech received $28 million in Series A funding from Novartis Venture Fund, BioAdvance Ventures and Frazier Healthcare Partners.

Transaction Overview

Company Information

Company Status

Private & Independent

Industry

Biopharmaceutical

Mailing Address

1004 West 9th Ave. 115
King Of Prussia, PA 19406
USA

Phone

484-590-5290

Website

www.merganserbiotech.com

Email Address

Not Recorded

Overview

Merganser Biotech is committed to the development of new medicines for the treatment of rare hematological and iron overload diseases.

Profile

Social Media

Company News

Facebook

YouTube

Management Team

Title

Name

Email & Social

Chief Executive Officer

Brian MacDonald

        

Chief Operating Officer

Remy Sukhija

        

VP - Bus. Development

Gene Merutka

        

Browse more venture capital transactions:

Prev: 2/19/2015: Firefly Games venture capital transaction
Next: 2/19/2015: Springpath venture capital transaction

Share this article

Where The Data Comes From

Our team works diligently to document every notable VC transaction. VC transactions reported here are derived from company press releases and news coverage. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.

Additional Resources for Entrepreneurs

Lists of Venture Capital and Private Equity Firms

Franchise Opportunities

Contributors

Business Glossary